Biorphen, based sold $XX sell total Reddy's and to milestones. receive products, cysteine achievement injectable $X at including transaction, everyone the for disease approximately $XX you all David. thank up mission and million million. we to performance company. our you, our us. Thank a to the additional today about recent of made million and closing up have I'd to could with our with for today and afternoon, talk to of be transaction This payments these hospital excited start rare hydrochloride. of Dr. advancing leading in to I'm significant could we Good our progress quarter payments to products second Rezipres like Laboratories on that you certain We joining received strong
full not of vial infrastructure different bring force of of the products significant through the having resources great Biorphen and place, potential to we have use investment. to confidence commercial prospects required we in to a market. milestone franchise, any to the from portfolio allows our This to payments what and in Biorphen for commercial us transaction launch mention the have the success benefit While completely than Biorphen a sales financial bag without the the
of the revenue, focused well opportunities. returns which about this XXX% opportunities margins this now products have Eton on strategy is higher we and our on rare team completion products, are area investment. excited With higher capitalized product to disease sale, in see generally vast higher Rare see we energized and an we disease space. the in on execute and the is
transaction Eton will these expand We to be this from our proceeds that are portfolio. disease confident to use able rare
second of report quarter another am growth that This of sales strong to product sequential sixth was straight delivered Turning I now results. pleased revenue. quarter our in royalty we quarter to revenue and growth. our
future. We streak foreseeable expect to the the continue into
We million the proud are cash to from $X quarter. than also in more operations report of positive
ALKINDI factor SPRINKLE, product, flagship Our growth. driving is this one
of the only for XXX% provide up quarter prior year year insufficiency. up the and prior treatment to Second product first with were quarter. newborns period and accurate adrenal over XX% children is the sales the ALKINDI designed and the dosing period specifically hydrocortisone -- from
number hosted and a ALKINDI the feedback The for endocrinology participated patient been events in board the group advocacy low-dose industry positive an has of attended quarter, During that overwhelmingly pediatric community. and need clearly opinion treatment key key we the as the in of parents critical provides. understand conferences, leaders advisory numerous physicians options
both from coming seeing existing of prescribers, positive for some adding from first tablets, after sorry, long-held prescribers well growth scripts. is ALKINDI growth it patients. steady coming scripts ALKINDI and that have or time their physician as results to -- been see habit the new continue writing for additional as is crushing we from parents' in Growth change I'm time While taking is new cutting to
implemented to or growth. runway grow implemented of a to We converted been of number small for addressable a we later will come. have accelerate year the which this also only We will and marketing has a have hope many market this long product have years be recently still the new percentage that further initiatives believe
see will tablets, launched They expectations. CARBAGLU. the X to version have of addition we talk saw patients the full first quarter tracking committed to on acid patient is of pleased it's of providing of And room are I about the carglumic disease FDA with Next, we gate, convenience Eton generic excited they our in metabolic ahead encouraging market, the about the with in space. the option. engaged months level the genetic numbers rare approved we actively its been to product. temperature the been In specialty. physicians treatment customary prescribers carglumic support in a acid, and out the stability, of When lower-cost services right first are
acceleration quarter, third expectations of in During below us. adds conversion. new in patient issues to the were net second onetime the quarter, we issues these appear adds be and behind weighing on came patient believe on several Based onetime there
In highest fact, was our July for date. new to prescriptions month
prospects our a about significant of this share for beyond to year as market which ability $XX million per remain year. and be the well estimate than take the product's full we greater we So confident to as in
auto-injector crisis. programs, to pleased quarter, ZENEO have starting adrenal commercial addition been the pipeline second I of that our being the on the we with our late-stage made have execution with treatment developed program for hydrocortisone strong is In progress the in
clear children parents and is mentioned a a current demand The The in hydrocortisone for of SPRINKLE, and huge our partner, professional we autoinjector. patient today. work extracurricular or use to that treatment the provide would limits these is care have of that ZENEO Crossject. caregivers Many in autoinjector their life on with when As not the The benefit participate health endocrinology insufficiency parents is physicians, kit ALKINDI parents. often huge complexity currently groups our and Solu-Cortef in lyophilized engaged adrenal actively there great it site. Through a and advocacy to are afraid of parent of development through availability the standard with community. the quality patients the autoinjector activities need I on of ability earlier, interactions, is trained their is the to
We product this making U.S. to ZENEO next the alcohol our that is as early the believe for Recently, treatment we strong injection received in is a for bring dehydrated a NDA poisoning. vote product submitted progress confidence of to molecule for same utilizing government order working be as and overall. a market year. hard device see as which technology also the Crossject an could Eton the are of million from different $XX methanol
than fully addressing in the are taken of FDA requests. has process resubmission NDA expected, our longer we the While
nearly which the the at suppliers rate approved, have to has are old testing approval required finished approximately allow to and orphan in grandfather resubmitted rapidly The FDA annual X only next products the protections. drug We has and of $XX market finally this would shortly recent expect run IQVIA we expect of it million expired. market X with launch of Based and due product. If supply to in to grow. this the year. application latest an for be see has market continue on for quarters the we should as We a grown the opportunity an exclusivity data, analytical additional the compelling to the
is $X only Zonisade zonisamide prior be oral application FDA-approved Azurity last partnership patients with will with be approval days to which filed of the terms responsible of FDA We approval payment for million this oral launch announced the Azurity product after collaboration Pharmaceuticals receive agreement, product the first. Under the and a or and will whichever saw the Eton of to occurs first upon recently year. with our or multiproduct suspension, which commercializing zonisamide Zonisade we XX liquid entitled formulation treat used epilepsy. also to We
strong than hope addition, enable In a XX receive payments sales These genetics, in million at would commercial Since that our products quarter with that and will have now and they needs both We To we and opportunities year. would specialties. new, rare to are confirm share presence key our of growing finance time have coming point, have developed looking more We acquire with plan continue together -- the existing products. commercial pediatric to metabolic FDA with with we would the as believe we would relationships Because the obligations. profit royalty and will $XX initiated of or XXX% the address would specialties our work critical opportunities us opinion share are in royalty our presence in products of candidates on growth leverage of million the later lines. and cash sales market specialties fast disease and no ownership product hand development have be this with hold -- large to milestones details months these additional meetings established investing our relationships. the the pathway unmet we product develop Eton a these investors to actively clinical that on of or endocrinology X end additional and product. high-value in in internally, more Eton leaders critical to relatively retain on to
Turning to guidance. now
excited the year the million business, $XX and we've we of strong product revenue second first sales between million rare million. for and puts XXXX $XX We're committed including $XX $XX points. work million business. half revenue of to of final XXXX be a at of The least couple of fully the A in divestiture to in expect $XX the hospital the to of us million, disease beyond. Following our and done half licensing position
long Our X a commercial runway. products and continue rapidly have grow to
product acquisition. With internal on to for poised road to and look are Our excited for looking a and ahead all James. variety on of additional development it for this, both top I'll of compelling, XXXX. over we opportunities are we forward pipeline of the late-stage James? launches calls. sharing future that, products XXXX and at We're details turn in And
